[Skip to Content]

Upstate Active Clinical Trials

Study Title:

E1A11 - Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

What is the purpose of the study?

This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib or carfilzomib together with lenalidomide and dexamethasone may kill more cancer cells

Upstate Institutional Review Board (IRB) Number:

624905

Study/Protocol ID:

E1A11

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Teresa C Gentile, MD, PhD

What is involved if I participate?

  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    No

ClinicalTrials.Gov ID:

NCT01863550

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Vanessa Gatmaitan
Phone: 315-464-5788
Email: gatmaitv@upstate.edu

Return to Previous Page || Search Again

Top